Abstract: The present invention relates to a method for moderately increasing the content of dimethyl disulfide in casein-containing processed cheese. The method includes the following steps: taking a cheese powder, adding chymosin for enzymolysis, and subjecting a material obtained after the enzymolysis to puffing and drying to obtain a modified cheese powder; preparing materials; taking the modified cheese powder, heating the modified cheese powder under stirring until the cheese powder is melt, adding sodium bicarbonate to adjust the pH to 6-7, and adding papain for enzymolysis; taking a material obtained after the enzymolysis, adding butter, a skimmed milk powder, fructo-oligosaccharide and water for mixing by stirring, and then adding an emulsifying salt, glutamine transaminase and salt for uniform heating and stirring to obtain a mixture; and subjecting the mixture to heat treatment, hot filling and cooling in sequence to obtain processed cheese.

Abstract: The present disclosure provides a transfer plate. The transfer plate includes a base film, and a dot array arranged on the base film and consisting of a plurality of dots. The base film includes an active region corresponding to a display region and a non-active region surrounding the active region. The dot array at the active region is of a first dot angle, and the dot array at the non-active region is of a second dot angle less than the first dot angle.

Abstract: The present disclosure provides a transfer plate. The transfer plate includes a base film, and a dot array arranged on the base film and consisting of a plurality of dots. The base film includes an active region corresponding to a display region and a non-active region surrounding the active region. The dot array at the active region is of a first dot angle, and the dot array at the non-active region is of a second dot angle less than the first dot angle.

Abstract: A method for enhancing a vaccine therapy effect by a vaccine composition. The method including a step of implanting ?-tricalcium phosphate in an inside of a body of a subject, and a step of administering the vaccine composition to the subject at the same time with or before or after the implanting step.

Abstract: The purpose is to provide an immunity-inducing agent which can be implanted or injected in vivo by a simple operation and is capable of activating the in vivo immunological actions without causing adverse side effects. An immunity-inducing agent comprising ?-tricalcium phosphate (?-TCP) having a porosity of 50% or less is implanted or injected in vivo, particularly in the vicinity of a lesion area (non-lesion area) such as cancer. Lymphocytes such as T cells, B cells and NK cells or a dendritic cell can be induced in the vicinity of ?-TCP, and a lymphadenoid tissue is formed in which lymphocytes are localized at a high density. Examples of the dosage form of the immunity-inducing agent include particles or granules having a particle or grain size of equal to or greater than 0.05 ?m and less than 25 ?m, as well as tablets or columellas.